NBRV vs. ETTX, ABEO, TRVI, RIGL, CAPR, PBYI, OGI, TELO, RPTX, and GALT
Should you be buying Nabriva Therapeutics stock or one of its competitors? The main competitors of Nabriva Therapeutics include Entasis Therapeutics (ETTX), Abeona Therapeutics (ABEO), Trevi Therapeutics (TRVI), Rigel Pharmaceuticals (RIGL), Capricor Therapeutics (CAPR), Puma Biotechnology (PBYI), Organigram (OGI), Telomir Pharmaceuticals (TELO), Repare Therapeutics (RPTX), and Galectin Therapeutics (GALT). These companies are all part of the "medical" sector.
Nabriva Therapeutics (NASDAQ:NBRV) and Entasis Therapeutics (NASDAQ:ETTX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their community ranking, valuation, profitability, earnings, risk, analyst recommendations, institutional ownership, media sentiment and dividends.
Entasis Therapeutics has a net margin of 0.00% compared to Nabriva Therapeutics' net margin of -148.11%. Entasis Therapeutics' return on equity of -145.48% beat Nabriva Therapeutics' return on equity.
Entasis Therapeutics has lower revenue, but higher earnings than Nabriva Therapeutics. Entasis Therapeutics is trading at a lower price-to-earnings ratio than Nabriva Therapeutics, indicating that it is currently the more affordable of the two stocks.
Nabriva Therapeutics received 297 more outperform votes than Entasis Therapeutics when rated by MarketBeat users. However, 64.86% of users gave Entasis Therapeutics an outperform vote while only 58.05% of users gave Nabriva Therapeutics an outperform vote.
0.3% of Nabriva Therapeutics shares are held by institutional investors. Comparatively, 6.9% of Entasis Therapeutics shares are held by institutional investors. 1.6% of Nabriva Therapeutics shares are held by insiders. Comparatively, 6.5% of Entasis Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Nabriva Therapeutics has a beta of 1.53, suggesting that its stock price is 53% more volatile than the S&P 500. Comparatively, Entasis Therapeutics has a beta of 1.33, suggesting that its stock price is 33% more volatile than the S&P 500.
In the previous week, Nabriva Therapeutics had 1 more articles in the media than Entasis Therapeutics. MarketBeat recorded 1 mentions for Nabriva Therapeutics and 0 mentions for Entasis Therapeutics. Nabriva Therapeutics' average media sentiment score of 0.00 equaled Entasis Therapeutics'average media sentiment score.
Summary
Entasis Therapeutics beats Nabriva Therapeutics on 8 of the 13 factors compared between the two stocks.
Get Nabriva Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for NBRV and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NBRV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Nabriva Therapeutics Competitors List
Related Companies and Tools
